Jim Cramer Says “Merck Is Terrific”

Merck & Co., Inc. (NYSE:MRK) was among Jim Cramer’s stock calls as he suggested that many red-hot stocks can keep making investors money. A caller asked whether they should stick with the stock or switch to another one. Cramer replied:

Okay, I’ve gotta tell you, this rotation out of healthcare is one of the most breathtaking rotations. We could be talking about a half dozen drug stocks, and they would all be the same. I think that Merck is at 13 times earnings. I think Merck is terrific. I don’t think that matters at all. I think the stock could drop another five, so you want to buy some and then leave, I like to say leave room. Hey, maybe divide by 10. It’s an $11 stock. Maybe it goes to 10 and a half.

Merck & Co., Inc. (NYSE:MRK) is a healthcare company that provides a wide range of human and veterinary pharmaceuticals, vaccines, and health solutions. TCW Relative Value Large Cap Fund stated the following regarding Merck & Co., Inc. (NYSE:MRK) in its fourth quarter 2025 investor letter:

The best performing stocks in the quarter were Alphabet†, Intel (INTC; 2.69%**), and Merck & Co., Inc. (NYSE:MRK) (MRK; 2.70%**). Merck & Co. shares jumped after the company reported better than expected third quarter revenues. Management attributed the beat to cost cutting initiatives and strong sales of its pneumonia vaccine.

While we acknowledge the risk and potential of MRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than MRK and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.